

Clinical Policy: Osilodrostat (Isturisa)

Reference Number: CP.PHAR.487

Effective Date: 09.01.20

Last Review Date: 08.22

Line of Business: Commercial, HIM, Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Osilodrostat (Isturisa[®]) is a cortisol synthesis inhibitor.

FDA Approved Indication(s)

Isturisa is a cortisol synthesis inhibitor indicated for the treatment of adult patients with Cushing's disease (CD) for whom pituitary surgery is not an option or has not been curative.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Isturisa is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Cushing's Disease (must meet all):

1. Diagnosis of CD;
2. Prescribed by or in consultation with an endocrinologist;
3. Age \geq 18 years;
4. Member meets one of the following (a or b):
 - a. Pituitary surgery has not been curative;
 - b. Member is not eligible for pituitary surgery;
5. Dose does not exceed 30 mg twice daily.

Approval duration: 6 months

B. Other diagnoses/indications

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. Cushing's Disease (must meet all):

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy (*see Appendix D*);
3. If request is for a dose increase, new dose does not exceed 30 mg twice daily.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.

Approval duration: Duration of request or 6 months (whichever is less); or

2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid, or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

CD: Cushing’s disease

FDA: Food and Drug Administration

UFC: urinary free cortisol

Appendix B: Therapeutic Alternatives

Not applicable

Appendix C: Contraindications/Boxed Warnings

None reported

Appendix D: General Information

- Treatment response for CD may be defined as reduction in 24-hour urinary free cortisol (UFC) levels and/or improvement in signs or symptoms of the disease. Maximum UFC reduction is typically seen by two months of treatment.
- Across sampled U.S. laboratories (Mayo Clinic Laboratories, LabCorp, Quest Diagnostics), 24-hour UFC adult reference values range from 3 to 64 mcg/24 h. The American Association of Neurological Surgeons notes that UFC levels higher than 50-100 mcg/24 h in adults suggest the presence of Cushing’s syndrome [inclusive of CD]. In this context, the Endocrine Society notes that 24-hour UFC levels may range from more than 5 times normal in severe cases to as low as 1.5 times normal in relatively mild cases.

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
CD	<u>Recommended Dosage, Titration, and Monitoring</u> <ul style="list-style-type: none"> • Initiate dosing at 2 mg orally twice daily, with or without food. 	60 mg/day

Indication	Dosing Regimen	Maximum Dose
	<ul style="list-style-type: none"> • Initially, titrate the dosage by 1 to 2 mg twice daily, no more frequently than every 2 weeks based on the rate of cortisol changes, individual tolerability and improvement in signs and symptoms of Cushing’s disease. If a patient tolerates Isturisa dosage of 10 mg twice daily and continues to have elevated 24-hour urine free cortisol (UFC) levels above upper normal limit, the dosage can be titrated further by 5 mg twice daily every 2 weeks. Monitor cortisol levels from at least two 24-hour urine free cortisol collections every 1-2 weeks until adequate clinical response is maintained. • The maintenance dosage of Isturisa is individualized and determined by titration based on cortisol levels and patient’s signs and symptoms. • The maintenance dosage varied between 2 mg and 7 mg twice daily in clinical trials. The maximum recommended maintenance dosage of Isturisa is 30 mg twice daily. • Once the maintenance dosage is achieved, monitor cortisol levels at least every 1-2 months or as indicated. <p><u>Dosage Interruptions and Modifications</u></p> <ul style="list-style-type: none"> • Decrease or temporarily discontinue Isturisa if urine free cortisol levels fall below the target range, there is a rapid decrease in cortisol levels, and/or patients report symptoms of hypocortisolism. If necessary, glucocorticoid replacement therapy should be initiated. • Stop Isturisa and administer exogenous glucocorticoid replacement therapy if serum or plasma cortisol levels are below target range and patients have symptoms of adrenal insufficiency. • If treatment is interrupted, re-initiate Isturisa at a lower dose when cortisol levels are within target ranges and patient symptoms have been resolved. 	

VI. Product Availability

Tablets: 1 mg, 5 mg, 10 mg

VII. References

1. Isturisa Prescribing Information. Lebanon, NJ: Recordati Rare Disease, Inc.; March 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212801s000lbl.pdf. Accessed May 4, 2022.
2. Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing's syndrome: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015; 100:2807.

3. Cushing’s syndrome/disease. American Association of Neurological Surgeons. Available at <https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Cushings-Disease>. Accessed March 24, 2020.
4. Biller BMK, Newell-Price J, Fleseriu M, et al. OR16-2 Osilodrostat treatment in Cushing's disease (CD): Results from a phase III, multicenter, double-blind, randomized withdrawal study (LINC 3). *Journal of the Endocrine Society*. 2019; 3(Suppl 1): OR16-2, <https://doi.org/10.1210/js.2019-OR16-2>.
5. Fleseriu M, Pivonello R, Young J, et al. Osilodrostat, a potent oral 11b-hydroxylase inhibitor: 22-week, prospective, phase II study in Cushing’s disease. *Pituitary*. 2016; 19: 138-148. DOI 10.1007/s11102-015-0692-z.
6. Fleseriu M, Auchus R, Bancos I, et al. Consensus on diagnosis and management of Cushing's disease: a guideline update. *Lancet Diabetes Endocrinol*. 2021 Dec; 9(12): 847-875.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created	04.21.20	08.20
3Q 2021 annual review: no significant changes; modified HIM.PHAR.21 to HIM.PA.154; references reviewed and updated.	04.05.21	08.21
3Q 2022 annual review: no significant changes; references reviewed and updated.	05.04.22	08.22

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a

discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2020 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.